Concomitant use of anabolic androgen steroids and cabotegravir/rilpivirine leading to virological failure and development of two-class resistance.
作者信息
Burger David, Wttewaal Eva, Oosterhof Piter, Stalenhoef Janneke
机构信息
Department of Pharmacy, Radboud Institute for Medical Innovations (RIMI), Radboud UMC, Nijmegen.
Department of Internal Medicine.
出版信息
AIDS. 2024 Sep 1;38(11):1728-1729. doi: 10.1097/QAD.0000000000003959. Epub 2024 Aug 1.
Abstract
摘要
相似文献
1
Concomitant use of anabolic androgen steroids and cabotegravir/rilpivirine leading to virological failure and development of two-class resistance.同时使用合成代谢雄激素类固醇与卡博特韦/利匹韦林导致病毒学失败和产生两类耐药性。
AIDS. 2024 Sep 1;38(11):1728-1729. doi: 10.1097/QAD.0000000000003959. Epub 2024 Aug 1.
2
Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine.转换为长效卡博特韦和rilpivirine后病毒学失败病例的特征分析。
J Antimicrob Chemother. 2024 Aug 1;79(8):2074-2076. doi: 10.1093/jac/dkae187.
3
Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.长效卡替拉韦和利匹韦林注射剂转换后发生病毒学失败：深入分析。
Clin Infect Dis. 2024 Jul 19;79(1):189-195. doi: 10.1093/cid/ciae016.
4
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort.每两个月一次长效注射卡博特韦和利匹韦林作为荷兰HIV-1维持治疗的有效性：荷兰雅典娜全国观察性队列研究结果
Lancet HIV. 2025 Jan;12(1):e40-e50. doi: 10.1016/S2352-3018(24)00269-8.
5
Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results.长效肌内维持治疗用卡替拉韦和利匹韦林的真实世界数据与 3 期研究结果一致。
J Antimicrob Chemother. 2024 Nov 4;79(11):2932-2938. doi: 10.1093/jac/dkae308.
6
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。
Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
7
Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.每月注射用卡替拉韦/利匹韦林治疗成人 HIV 感染。
J Am Assoc Nurse Pract. 2022 Jul 1;34(7):918-923. doi: 10.1097/JXX.0000000000000729.
8
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine.使用长效注射用卡博特韦和利匹韦林进行病毒学监测的适宜性。
J Antimicrob Chemother. 2024 Oct 1;79(10):2720-2724. doi: 10.1093/jac/dkae257.
9
A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.肌肉注射卡替拉韦和利匹韦林长效复方制剂的患者中诊断出的 HIV 合并感染。
Clin Infect Dis. 2024 Jul 19;79(1):196-197. doi: 10.1093/cid/ciad757.
10
Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.在一名病毒学未得到抑制的患者中开始使用卡博特韦-利匹韦林治疗。
AIDS. 2022 Aug 1;36(10):1475-1476. doi: 10.1097/QAD.0000000000003273.
本文引用的文献
1
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.长效卡博特韦和rilpivirine的真实世界谷浓度及有效性：瑞士的一项多中心前瞻性观察研究
Lancet Reg Health Eur. 2023 Dec 13;36:100793. doi: 10.1016/j.lanepe.2023.100793. eCollection 2024 Jan.
2
Development, validation and clinical implementation of a UPLC-MS/MS bioanalytical method for simultaneous quantification of cabotegravir and rilpivirine E-isomer in human plasma.建立、验证并临床应用 UPLC-MS/MS 法，用于人血浆中卡替拉韦和利匹韦林 E-对映异构体的同时定量分析。
J Pharm Biomed Anal. 2024 Jan 20;238:115832. doi: 10.1016/j.jpba.2023.115832. Epub 2023 Nov 4.
3
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.扩展多变量模型以辅助长效卡替拉韦+利匹韦林治疗的患者选择：与病毒学失败相关的患者、药物浓度和病毒因素组合的临床效用。
Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370.
4
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.长效卡替拉韦和利匹韦林每 2 个月给药 1 次治疗人类免疫缺陷病毒 1 型感染成人患者：ATLAS-2M 研究 152 周结果，这是一项随机、开放标签、3b 期、非劣效性研究。
Clin Infect Dis. 2023 May 3;76(9):1646-1654. doi: 10.1093/cid/ciad020.
5
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.长效卡博特韦和rilpivirine的实际治疗浓度监测：瑞士一项正在进行的前瞻性观察研究的初步结果。
Pharmaceutics. 2022 Jul 29;14(8):1588. doi: 10.3390/pharmaceutics14081588.
6
Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine.性相关激素对药物代谢酶的调节： transgender medicine 的临床意义。
Trends Pharmacol Sci. 2022 Jul;43(7):582-592. doi: 10.1016/j.tips.2022.03.006. Epub 2022 Apr 26.
7
Sex and Gender Differences in Clinical Pharmacology: Implications for Transgender Medicine.临床药理学中的性别差异：对跨性别医学的影响。
Clin Pharmacol Ther. 2021 Oct;110(4):897-908. doi: 10.1002/cpt.2234. Epub 2021 May 2.
8
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.探索长效卡替拉韦和利匹韦林治疗 HIV-1 病毒学失败的预测因素：多变量分析。
AIDS. 2021 Jul 15;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883.
9
Propranolol metabolism in normal subjects: association with sex steroid hormones.正常受试者体内普萘洛尔的代谢：与性类固醇激素的关联。
Clin Pharmacol Ther. 1994 Aug;56(2):127-32. doi: 10.1038/clpt.1994.115.
Zotero 插件